Alzheimer's DiseasePhase 2NCT00814346
Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions
A Phase 2 study testing EGb761® in people with Alzheimer's Disease and Cognitive Impairment, run by Ipsen at 8 sites in France.
Trial summary
The aim of the study is to evaluate the effect of EGb761®, in comparison to placebo, on cerebral glucose metabolism, in three groups of elderly patients: newly diagnosed mild Alzheimer's disease (AD), memory complaint patients with cognitive impairment (MC) and memory complaint patients cognitively normal (CNE). Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Alzheimer's Disease, Cognitive Impairment
- What is being tested?
- EGb761®
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 49 participants
- Where
- 8 sitesFrance
- Study dates
- Oct 2008to Jul 2012
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Group Specific Inclusion Criteria:
- Cognitively normal elderly (CNE)
- Spontaneous memory complaint by patient,
- Mini-Mental State Exam score ≥ 28.
- Clinical Dementia Rating = 0.
- No Diagnostic And Statistical Manual Of Mental Disorders, Fourth Edition (DSMIV) criteria for Dementia.
Show all 20Show fewer
- Memory complaints (MC) :
- Spontaneous memory complaint by patient
- Mini-Mental State Exam score ≥ 25
- Clinical Dementia Rating 0.5.
- No DSMIV criteria for Dementia.
- Mild Alzheimer's Disease (AD):
- Mini Mental Status Examination (MMSE) between 20 and 28 (inclusive).
- Clinical Dementia Rating ≥ 1.0
- DSMIV criteria for Dementia.
- National Institute of Neurological and Communicative Diseases and Stroke / Alzheimer's Disease and Related Disorders Association(NINCDS/ADRDA) criteria for probable AD.
- Newly diagnosed patients without treatment by Cholinesterase Inhibitors or Memantine.
- ≥ 65 years of age, both sex
- Geriatric Depression Scale (GDS) < 15
- Informed consent signed by the patient or, if necessary by legal representative
Who cannot join
- Contraindication to Magnetic Resonance Imaging (MRI) and/or Positron-Emission Tomography (PET) scan
- Forbidden Concomitant medications (Cholinesterase inhibitors and memantine, Specific psychoactive medications,e.g., neuroleptics, chronic anxiolytics including meprobamate, or sedative hypnotics other than benzodiazepines, Monoamine oxidase inhibitors (MAOIs) including selective MAOIs. Drugs acting on cerebral nervous system, Antidiabetes medications , Antioxidants medications, Medications known to interfere with cognitive evaluations
- Significant neurological disease and psychiatric disorders/psychotic feature
- Significant medical illness
Trial locations and contacts
8 sites in 1 country.
8 sites in 1 country
France8 sites
Hôpital Corentin Celton 4 parvis Corentin Celton
Issy-les-Moulineaux
Hôpital de Juvisy
Juvisy-sur-Orge
CMPI "Les Rives de Seine"
Le Vésinet
Centre Hospitalier d'Orsay 4 place du Général Leclerc
Orsay
Private practice
Paris, 75009
Hôpital Broca 54-56 rue Pascal
Paris, 75013
Observatoire de l'âge
Paris
Hôpital Paul Brousse 12 av Paul-Vaillant-Couturier
Villejuif
About this study
Official title: Effect of Oral EGb761® on Brain Glucose Metabolism in Three Groups of Elderly With Memory Complaint, Mild Alzheimer's Disease, and Cognitively Normal Elderly. Phase II, Randomised, Double-blind, Parallel Groups, Placebo-controlled Study
The aim of the study is to evaluate the effect of EGb761®, in comparison to placebo, on cerebral glucose metabolism, in three groups of elderly patients: newly diagnosed mild Alzheimer's disease (AD), memory complaint patients with cognitive impairment (MC) and memory complaint patients cognitively normal (CNE). The first phase includes four weeks treatment with EGb761® for all groups, with change in brain glucose metabolism at month 1 using 18 FDG-PET, as primary endpoint which will be followed by an open 17 months follow-up (FU) period with EGb761® treatment in MC and CNE patients.
- Conditions
- Alzheimer's Disease, Cognitive Impairment
- Being tested
- EGb761®, Placebo
- Keywords
- Mild Alzheimer's disease (AD) patients, Memory complaint patients with cognitive impairment (MC), Memory complaint patients cognitively normal (CNE)
- Medical subject headings
- Alzheimer Disease, Cognitive Dysfunction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EGb761®Drug
Four weeks for AD patients, 18 months for MC and CNE patients
PlaceboDrug
Placebo 1 tablet BID
| Study group | Role | What they receive |
|---|---|---|
| EGb 120 mg | Active comparator | Not described Receives: Drug: EGb761® |
| Placebo | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)
Following statistical parametric mapping (SPM) analyses were performed by the Commissariat à l'Energie Atomique (CEA):
- The comparison between treatment groups separately for each group of elderly subjects (CNE and MC groups only)
- The comparison between the two groups of elderly subjects (CNE and MC groups only) by treatment group
FDG PET demonstrates reductions in the cerebral glucose metabolism that may occur a few years before the overt clinical manifestation of disease.
SUVBSA2 = [Brain radioactivity (Bq/cc)] / [Injected dose (MBq)/BSA2] x [Blood glucose (g/l)]
BSA2(m^2) = 0.007184 x Height (cm)^0.35 x weight (kg)^0.80
Standardized Uptake Value (SUV) Body Surface Area (BSA)
Measured: From Baseline (Month 0) to Week 4 (Month 1) - Double blind phase
Secondary outcomes (27)
Change in Brain Glucose Metabolism in the MC and CNE Groups
Brain glucose metabolism measured by 18FDG PET
SUVBSA2 = [Brain radioactivity (Bq/cc)] / [Injected dose (MBq)/BSA2] x [Blood glucose (g/l)]
BSA2(m^2) = 0.007184 x Height (cm)^0.35 x weight (kg)^0.80
Measured: From Baseline (Month 0) to Month 18
Change in Cognitive Tests-Clinical Dementia Rating (CDR) Score in MC and CNE Groups
CDR is a structured interview to collect information regarding subject's memory in a standard way from both the patient and the helper. Scores are calculated using below scale; q CDR=No dementia (score: 0), q CDR=Very mild dementia (score: 0.5), q CDR=Mild dementia (score: 1), q CDR=Moderate dementia (score: 2) and q CDR=Severe dementia (score: 3).
Measured: From Baseline (Month 0) to Month 9
Change in Cognitive Tests-Geriatric Depression Scale (GDS) Score in MC and CNE Groups
The Geriatric Depression Scale is a self-administered depression scale, which was developed as a basic screening measure for depression in older adults. By "yes" or "no" answers, scores permit to classify patients into groups of "severely depressed" (score of 21 to 30), "moderately depressed" (score of 11 to 20) and "normal" (score of 0 to10). It takes10 to 15 minutes to administer.
Measured: From Baseline (Month 0) to Month 9
Change in Cognitive Tests-Verbal Fluency in MC and CNE Groups
Subjects completed a verbal fluency test. Higher scores represent higher levels of verbal fluency. Minimum score=0 and Maximum score= N/A.
Letter fluency: this task consists of enouncing as many words as possible that begin with a given letter of the alphabet. Participants are not allowed to use proper names.
Categorical fluency: in this task participants are asked to list as many words as possible that belong to a given semantic category (e.g. animals, fruits, towns) Each condition foresees 60 sec of word generation time. The score corresponds to the number of words correctly given. The verbal fluency task measures semantic storage and executive retrieval functions.
Measured: From Baseline (Month 0) to Month 9
Change in Cognitive Tests-Mini Mental Status Examination (MMSE) Score in MC and CNE Groups
MMSE is a brief screening instrument used to assess cognitive function in elderly participants. It assesses orientation, memory, attention, ability to name objects, follow verbal and written commands, write a sentence, and copy figures. Total score ranges from 0 to 30, with a lower score indicating greater disease severity.
Measured: From Baseline (Month 0) to Month 9
Change in Cognitive Tests-Clock Drawing Test Score in MC and CNE Groups
Clock drawing test is a visuo-constructive task, where subjects are asked to draw the face of a clock in a pre-drawn circle and then to draw in the arms to denote 16:45 (a quarter to five). The drawing can then be evaluated by a quantitative scoring method, which is based on the degree of completion of the drawing. The scoring system ranges from 0 to 6 with higher scores reflecting a greater number of errors and more impairment.
Measured: From Baseline (Month 0) to Month 9
Change in Cognitive Tests-Cube Drawing Test Score in MC and CNE Groups
Cube drawing: Subjects are asked to draw a cube by heart. In case of failure, a model of a cube is given to the subjects to copy.
The score system ranges from 0 (worse score) to 6 (best score). Score calculation is following: 1 point by face with 4 sides, 2 points for each face where each angle should be respected.
Measured: From Baseline (Month 0) to Month 9
Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of the Free and Cued Selective Reminding Test (FCSRT)
Free and Cued Selective Reminding Test (FCSRT) Assessment of verbal episodic memory. By this test performances in free recalls, cued recalls and in a recognition task can be analysed, because the process of encoding is controlled.
Subjects are asked to remember a list of 16 words. Three tasks of free and cued recalls, as well as one recognition task and one delayed recall give the scores.
Total recall is obtained by the addition of cued recalls to free recalls. Maximum score is 48 for immediate: 16 words X 3 corresponding to immediate free recall + immediate cued recall + immediate recognition test.
Maximum score is 64 (better score) when delayed recall : 16 words X 4 . The minimum score is 0 (worse).
Measured: From Baseline (Month 0) to Month 9
Change in Cognitive Tests-Age-Adjusted Logical Memory (MEM III) in MC and CNE Groups
Subjects are asked to memorize two short stories, one consisting of 24, the other one of 26 information units. After the stories have been read aloud by the investigator, subjects are asked to enounce all items of information they can remember (free recall). Correctly reported items are added for each story. This test applies analytical capacities, as well as auditive and verbal synthesis, working memory and episodic memory.
Score range from 0(worst) to 75 (better).
Measured: From Baseline (Month 0) to Month 9
Change in Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS) in MC and CNE Groups
Wechsler Adult Intelligence Scale (WAIS) In this test subjects are asked to say how two seemingly dissimilar items might in fact be similar (14 item couples). This test involves especially abstract thinking and concept capacities.
Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS): 19 tests on similarities. The items 1 to 5 are graded from 1 (good) to 0 (bad), and the items 6 to 19 are graded from 2 (good) to 0 (bad). Item 6 and 7 can be repeated. At the end, the worst total score is 0, the best total score is 33.
Measured: From Baseline (Month 0) to Month 9
Change in Cognitive Tests-Time to Perform Trail Making Test (TMT) in MC and CNE Groups
TMT is a neuropsychological test of visual attention and task switching. The task requires a subject to 'connect-the-dots' of 25 consecutive numbers (1,2,3,etc.) on a sheet of paper or computer screen. The goal of the subject is to finish the test as quickly as possible and the time taken to complete the test is used as the primary performance metric (in seconds). The maximum time allowed is 300 seconds. A negative change score indicates improvement.
First, in the TMT A, the subject has to connect numbers increasingly as fast as possible.
The TMT B requires the subject to connect and letters in an alternating pattern (1-A-2-B-3-C, etc.) in as little time as possible.
Measured: From Baseline (Month 0) to Month 9
Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to the DSM IV (Diagnostic of Dementia)
The Diagnostic and Statistical Manual of Mental Disorders: 4th Edition of the American Psychiatric Association (DSM-IV, 1994) also outlines diagnostic criteria for dementia of the Alzheimer's type that are generally consistent with the NINCDS-ADRDA criteria.
National Institute of Neurological and Communicative Diseases and Stroke / Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA)
Measured: At Month 9
Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to NINCDS-ADRDA (Diagnostic of Alzheimer's)
The most widely accepted diagnostic criteria for probable AD are those offered by the National Institute of Neurological and Communicative Disorders and Stroke and by the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA; McKhann et al., 1984). These criteria include the presence of dementia established by clinical examination and confirmed by neuropsychological testing. The dementia is described as involving multiple, progressive cognitive deficits in older persons in the absence of disturbances of consciousness, presence of psychoactive substances, or any other medical, neurological, or psychiatric conditions that might in and of themselves account for these progressive deficits.
Measured: At Month 9
Change in Cognitive Tests-CDR Score in MC and CNE Groups
CDR is a structured interview to collect information regarding subject's memory in a standard way from both the patient and the helper. Scores are calculated using below scale; q CDR=No dementia (score: 0), q CDR=Very mild dementia (score: 0.5), q CDR=Mild dementia (score: 1), q CDR=Moderate dementia (score: 2) and q CDR=Severe dementia (score: 3)
Measured: From Baseline (Month 0) to Month 18
Change in Cognitive Tests-GDS Score in MC and CNE Groups
The Geriatric Depression Scale is a self-administered depression scale, which was developed as a basic screening measure for depression in older adults. By "yes" or "no" answers, scores permit to classify patients into groups of "severely depressed" (score of 21 to 30), "moderately depressed" (score of 11 to 20) and "normal" (score of 0 to10). It takes10 to 15 minutes to administer.
Measured: From Baseline (Month 0) to Month 18
Change in Cognitive Tests-Verbal Fluency in MC and CNE Groups
Subjects completed a verbal fluency test. Higher scores represent higher levels of verbal fluency. Minimum score=0 and Maximum score= N/A.
Letter fluency: this task consists of enouncing as many words as possible that begin with a given letter of the alphabet. Participants are not allowed to use proper names.
Categorical fluency: in this task participants are asked to list as many words as possible that belong to a given semantic category (e.g. animals, fruits, towns) Each condition foresees 60 sec of word generation time. The score corresponds to the number of words correctly given. The verbal fluency task measures semantic storage and executive retrieval functions.
Measured: From Baseline (Month 0) to Month 18
Change in Cognitive Tests-MMSE Score in MC and CNE Groups
MMSE is a brief screening instrument used to assess cognitive function in elderly participants. It assesses orientation, memory, attention, ability to name objects, follow verbal and written commands, write a sentence, and copy figures. Total score ranges from 0 to 30, with a lower score indicating greater disease severity.
Measured: From Baseline (Month 0) to Month 18
Change in Cognitive Tests-Clock Drawing Test Score in MC and CNE Groups
Clock drawing test is a visuo-constructive task, where subjects are asked to draw the face of a clock in a pre-drawn circle and then to draw in the arms to denote 16:45 (a quarter to five). The drawing can then be evaluated by a quantitative scoring method, which is based on the degree of completion of the drawing. The scoring system ranges from 0 to 6 with higher scores reflecting a greater number of errors and more impairment.
Measured: From Baseline (Month 0) to Month 18
Change in Cognitive Tests-Cube Drawing Test Score in MC and CNE Groups
Cube drawing: Subjects are asked to draw a cube by heart. In case of failure, a model of a cube is given to the subjects to copy.
The score system ranges from 0 (worse score) to 6 (best score). Score calculation is following: 1 point by face with 4 sides, 2 points for each face where each angle should be respected.
Measured: From Baseline (Month 0) to Month 18
Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of FCSRT
Free and Cued Selective Reminding Test (FCSRT) Assessment of verbal episodic memory. By this test performances in free recalls, cued recalls and in a recognition task can be analysed, because the process of encoding is controlled.
Subjects are asked to remember a list of 16 words. Three tasks of free and cued recalls, as well as one recognition task and one delayed recall give the scores.
Total recall is obtained by the addition of cued recalls to free recalls. Maximum score is 48 for immediate: 16 words X 3 corresponding to immediate free recall + immediate cued recall + immediate recognition test.
Maximum score is 64 (better score) when delayed recall : 16 words X 4 . The minimum score is 0 (worse).
Measured: From Baseline (Month 0) to Month 18
Change in Cognitive Tests-Age-Adjusted Logical Memory (MEM III) in MC and CNE Groups
Subjects are asked to memorize two short stories, one consisting of 24, the other one of 26 information units. After the stories have been read aloud by the investigator, subjects are asked to enounce all items of information they can remember (free recall). Correctly reported items are added for each story. This test applies analytical capacities, as well as auditive and verbal synthesis, working memory and episodic memory.
Score range from 0(worst) to 75 (better).
Measured: From Baseline (Month 0) to Month 18
Change in Cognitive Tests-Age-Adjusted WAIS in MC and CNE Groups
Wechsler Adult Intelligence Scale (WAIS) In this test subjects are asked to say how two seemingly dissimilar items might in fact be similar (14 item couples). This test involves especially abstract thinking and concept capacities.
Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS): 19 tests on similarities. The items 1 to 5 are graded from 1 (good) to 0 (bad), and the items 6 to 19 are graded from 2 (good) to 0 (bad). Item 6 and 7 can be repeated. At the end, the worst total score is 0, the best total score is 33.
Measured: From Baseline (Month 0) to Month 18
Change in Cognitive Tests-Time to Perform TMT in MC and CNE Groups
TMT is a neuropsychological test of visual attention and task switching. The task requires a subject to 'connect-the-dots' of 25 consecutive numbers (1,2,3,etc.) on a sheet of paper or computer screen. The goal of the subject is to finish the test as quickly as possible and the time taken to complete the test is used as the primary performance metric (in seconds). The maximum time allowed is 300 seconds. A negative change score indicates improvement.
First, in the TMT A, the subject has to connect numbers increasingly as fast as possible.The TMT B requires the subject to connect and letters in an alternating pattern (1-A-2-B-3-C, etc.) in as little time as possible.
Measured: From Baseline (Month 0) to Month 18
Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to the DSM IV (Diagnostic of Dementia)
The Diagnostic and Statistical Manual of Mental Disorders: 4th Edition of the American Psychiatric Association (DSM-IV, 1994) also outlines diagnostic criteria for dementia of the Alzheimer's type that are generally consistent with the NINCDS-ADRDA criteria.
Measured: At Month 18
Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to NINCDS-ADRDA (Diagnostic of Alzheimer's)
The most widely accepted diagnostic criteria for probable AD are those offered by the National Institute of Neurological and Communicative Disorders and Stroke and by the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA; McKhann et al., 1984). These criteria include the presence of dementia established by clinical examination and confirmed by neuropsychological testing. The dementia is described as involving multiple, progressive cognitive deficits in older persons in the absence of disturbances of consciousness, presence of psychoactive substances, or any other medical, neurological, or psychiatric conditions that might in and of themselves account for these progressive deficits.
Measured: At Month 18
Incidence of Adverse Events (AEs)
The relationship of an adverse event to the study medication will be classified according to the following criteria:
Related : reports including good reasons and sufficient information (e.g. temporal relationship, dose-response relationship, pharmacology, positive de-challenge and/or re-challenge) to assume a causal relationship with the study drug in the sense that it is plausible, conceivable, or likely
Not related: reports including good reasons and sufficient information (e.g. no temporal relationship and/or attributable to concurrent disease or other drugs) to rule out a causal relationship with the study drug.
Measured: Up to Month 18
Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel Size
Evolution of brain morphology (degree of cortical atrophy) after 18 months with EGb761, using MRI voxel based morphometry
Measured: From Baseline (Month 0) to Month 18
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Dec 2008 (estimated)
- Study startOct 2008
- Primary completionJul 2012
- Study completionJul 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Alzheimer's DiseaseStudies of the same condition, open and under way.
- More trials run by IpsenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 49 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ipsen
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Ipsen Medical Director, Study director, Ipsen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00814346
- Sponsor's protocol ID
- 2-39-00240-134
- Other IDs
- 2007-005377-63
- Status last verified
- Jan 2019
- First submitted
- 23 Dec 2008
- Last updated
- 8 Feb 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Feb 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Oral EGb761® on Brain Glucose Metabolism in Three Groups of Elderly With Memory Complaint, Mild Alzheimer's Disease, and Cognitively Normal Elderly. Phase II, Randomised, Double-blind, Parallel Groups, Placebo-controlled Study
- ClinicalTrials.gov ID
- NCT00814346
- Acronym / sponsor ID
- 2-39-00240-134
- Conditions
- Alzheimer's Disease, Cognitive Impairment
- Keywords
- Mild Alzheimer's disease (AD) patients, Memory complaint patients with cognitive impairment (MC), Memory complaint patients cognitively normal (CNE)
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 49 participants (actual)
- Lead sponsor
- IpsenIndustry (pharma, biotech, devices)
- Study start
- Oct 2008
- Primary completion
- Jul 2012 (actual)
- Study completion
- Jul 2012 (actual)
- First posted
- 24 Dec 2008 (estimated)
- Results
- Posted 28 Mar 2016
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to evaluate the effect of EGb761®, in comparison to placebo, on cerebral glucose metabolism, in three groups of elderly patients: newly diagnosed mild Alzheimer's disease (AD), memory complaint patients with cognitive impairment (MC) and memory complaint patients cognitively normal (CNE). The first phase includes four weeks treatment with EGb761® for all groups, with change in brain glucose metabolism at month 1 using 18 FDG-PET, as primary endpoint which will be followed by an open 17 months follow-up (FU) period with EGb761® treatment in MC and CNE patients.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| EGb 120 mg | Active comparator | Drug: EGb761® |
| Placebo | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (20 listed)
- Group Specific Inclusion Criteria:
- Cognitively normal elderly (CNE)
- Spontaneous memory complaint by patient,
- Mini-Mental State Exam score ≥ 28.
- Clinical Dementia Rating = 0.
Key exclusion criteria (4 listed)
- Contraindication to Magnetic Resonance Imaging (MRI) and/or Positron-Emission Tomography (PET) scan
- Forbidden Concomitant medications (Cholinesterase inhibitors and memantine, Specific psychoactive medications,e.g., neuroleptics, chronic anxiolytics including meprobamate, or sedative hypnotics other than benzodiazepines, Monoamine oxidase inhibitors (MAOIs) including selective MAOIs. Drugs acting on cerebral nervous system, Antidiabetes medications , Antioxidants medications, Medications known to interfere with cognitive evaluations
- Significant neurological disease and psychiatric disorders/psychotic feature
- Significant medical illness
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EGb761®Four weeks for AD patients, 18 months for MC and CNE patients | Drug | EGb 120 mg |
| PlaceboPlacebo 1 tablet BID | Drug | Placebo |
Primary outcome
Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)
Time frame: From Baseline (Month 0) to Week 4 (Month 1) - Double blind phase
Following statistical parametric mapping (SPM) analyses were performed by the Commissariat à l'Energie Atomique (CEA): * The comparison between treatment groups separately for each group of elderly subjects (CNE and MC groups only) * The comparison between the two groups of elderly subjects (CNE and MC groups only) by treatment group FDG PET demonstrates reductions in the cerebral glucose metabolism that may occur a few years before the overt clinical manifestation of disease. SUVBSA2 = [Brain radioactivity (Bq/cc)] / [Injected dose (MBq)/BSA2] x [Blood glucose (g/l)] BSA2(m^2) = 0.007184 x Height (cm)^0.35 x weight (kg)^0.80 Standardized Uptake Value (SUV) Body Surface Area (BSA)
27 secondary outcomes
Change in Brain Glucose Metabolism in the MC and CNE Groups
Time frame: From Baseline (Month 0) to Month 18
Change in Cognitive Tests-Clinical Dementia Rating (CDR) Score in MC and CNE Groups
Time frame: From Baseline (Month 0) to Month 9
Change in Cognitive Tests-Geriatric Depression Scale (GDS) Score in MC and CNE Groups
Time frame: From Baseline (Month 0) to Month 9
Change in Cognitive Tests-Verbal Fluency in MC and CNE Groups
Time frame: From Baseline (Month 0) to Month 9
Change in Cognitive Tests-Mini Mental Status Examination (MMSE) Score in MC and CNE Groups
Time frame: From Baseline (Month 0) to Month 9
Change in Cognitive Tests-Clock Drawing Test Score in MC and CNE Groups
Time frame: From Baseline (Month 0) to Month 9
Change in Cognitive Tests-Cube Drawing Test Score in MC and CNE Groups
Time frame: From Baseline (Month 0) to Month 9
Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of the Free and Cued Selective Reminding Test (FCSRT)
Time frame: From Baseline (Month 0) to Month 9
Change in Cognitive Tests-Age-Adjusted Logical Memory (MEM III) in MC and CNE Groups
Time frame: From Baseline (Month 0) to Month 9
Change in Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS) in MC and CNE Groups
Time frame: From Baseline (Month 0) to Month 9
Change in Cognitive Tests-Time to Perform Trail Making Test (TMT) in MC and CNE Groups
Time frame: From Baseline (Month 0) to Month 9
Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to the DSM IV (Diagnostic of Dementia)
Time frame: At Month 9
Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to NINCDS-ADRDA (Diagnostic of Alzheimer's)
Time frame: At Month 9
Change in Cognitive Tests-CDR Score in MC and CNE Groups
Time frame: From Baseline (Month 0) to Month 18
Change in Cognitive Tests-GDS Score in MC and CNE Groups
Time frame: From Baseline (Month 0) to Month 18
Change in Cognitive Tests-Verbal Fluency in MC and CNE Groups
Time frame: From Baseline (Month 0) to Month 18
Change in Cognitive Tests-MMSE Score in MC and CNE Groups
Time frame: From Baseline (Month 0) to Month 18
Change in Cognitive Tests-Clock Drawing Test Score in MC and CNE Groups
Time frame: From Baseline (Month 0) to Month 18
Change in Cognitive Tests-Cube Drawing Test Score in MC and CNE Groups
Time frame: From Baseline (Month 0) to Month 18
Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of FCSRT
Time frame: From Baseline (Month 0) to Month 18
Change in Cognitive Tests-Age-Adjusted Logical Memory (MEM III) in MC and CNE Groups
Time frame: From Baseline (Month 0) to Month 18
Change in Cognitive Tests-Age-Adjusted WAIS in MC and CNE Groups
Time frame: From Baseline (Month 0) to Month 18
Change in Cognitive Tests-Time to Perform TMT in MC and CNE Groups
Time frame: From Baseline (Month 0) to Month 18
Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to the DSM IV (Diagnostic of Dementia)
Time frame: At Month 18
Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to NINCDS-ADRDA (Diagnostic of Alzheimer's)
Time frame: At Month 18
Incidence of Adverse Events (AEs)
Time frame: Up to Month 18
Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel Size
Time frame: From Baseline (Month 0) to Month 18
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Feb 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Alzheimer's Disease
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
RecruitingObservational study
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Alzheimer's Disease (AD)
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
RecruitingPhase 3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Alzheimer's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ipsen Medical Director study director
Ipsen
8 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing EGb761® in people with Alzheimer's Disease and Cognitive Impairment, run by Ipsen at 8 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 20 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Feb 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 8 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 28 Mar 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET) (time frame: From Baseline (Month 0) to Week 4 (Month 1) - Double blind phase). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Feb 2019.